Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 3 December 2008, doi:10.1136/bmj.a1321
Cite this as: BMJ 2008;337:a1321
Geoff Watts, freelance journalist
1 London
geoff@scileg.freeserve.co.uk
Surgeons in Spain have recently transplanted a bioengineered human airway. But theres often much hype surrounding regenerative medicine. Geoff Watts investigates
| The first 150 words of the full text of this article appear below. |
With a clutch of new university departments, a growing number of small biotechnology companies, a dedicated journal and regular outbursts of press hoopla, regenerative medicine is on a roll. From diabetes to Parkinsons disease, from ailing hearts to failing knees, enthusiasts foresee new remedies for many of the common failures of flesh and bone.
The ambition of regenerative medicine—the reversal of age related, disease induced, and other bodily impairments—is hardly new. Varieties of "live cell therapy" dating back to the 1930s once lured the rich and famous to exclusive Swiss clinics to pay for expensive injections of heaven knows what. Such optimistic, if not foolhardy, leaps in the dark are a world away from current hopes and claims: the product of hard won insights into the biology of stem cells, and the genetic basis of their unique properties. And then there was the recent transplant of a bioengineered bronchus by
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?